Imvaria, Inc.
IMVARIA Inc. is a pioneering health tech company specializing in AI-driven digital biomarker solutions for serious diseases, including lung fibrosis and interstitial lung disease (ILD). Founded in 2019 by physician-engineers from Google and Stanford University, the company aims to transform clinical decision-making into data science, enabling earlier and more accurate diagnoses while reducing invasive procedures. IMVARIA's solutions, such as Fibresolve and ScreenDx, are FDA-authorized AI tools that assist clinicians in non-invasive diagnosis and assessment of lung conditions, supporting better patient outcomes and healthcare efficiency.
Industries
Nr. of Employees
small (1-50)
Patents
Machine learning models for automated diagnosis of disease database entities
US-12354749-B2
View DetailsMachine learning models for automated diagnosis of disease database entities
US-12315152-B2
View Details
Machine learning models for automated diagnosis of disease database entities
US-12354749-B2
View DetailsMachine learning models for automated diagnosis of disease database entities
US-12315152-B2
View DetailsProducts
Fibresolve
A software-only AI diagnostic adjunct that analyzes lung CT imaging to provide a diagnostic subtype classification in suspected interstitial lung disease, intended for use by clinicians qualified in lung disease to support pre-invasive assessment of idiopathic pulmonary fibrosis.
ScreenDx
An automated background AI algorithm that analyzes CT imaging to detect interstitial lung findings compatible with interstitial lung disease and flag cases for referral workflows.
Bronchosolve (investigational)
Investigational AI tool under research to automate risk assessment for suspicious pulmonary nodules detected on screening CTs.
Fibresolve
A software-only AI diagnostic adjunct that analyzes lung CT imaging to provide a diagnostic subtype classification in suspected interstitial lung disease, intended for use by clinicians qualified in lung disease to support pre-invasive assessment of idiopathic pulmonary fibrosis.
ScreenDx
An automated background AI algorithm that analyzes CT imaging to detect interstitial lung findings compatible with interstitial lung disease and flag cases for referral workflows.
Bronchosolve (investigational)
Investigational AI tool under research to automate risk assessment for suspicious pulmonary nodules detected on screening CTs.
Services
Remote service that accepts de-identified clinical cases (imaging and lab data), runs automated ML analyses, and returns diagnostic reports to referring clinicians as an adjunct to clinical assessment.
Remote service that accepts de-identified clinical cases (imaging and lab data), runs automated ML analyses, and returns diagnostic reports to referring clinicians as an adjunct to clinical assessment.
Expertise Areas
- AI biomarker development
- Clinical imaging diagnostics for ILD and IPF
- SaMD development and commercialization
- Regulatory strategy for medical AI (De Novo and 510(k))
Key Technologies
- Deep learning and convolutional neural networks
- Multi-modal data fusion (imaging + labs + clinical data)
- CT image analysis and pattern recognition
- Cloud-based analytics and centralized processing
News & Updates
IMVARIA reported results from multi-site clinical experiences with Fibresolve, the first FDA-authorized AI adjunctive diagnostic service for lung fibrosis, presented at ATS 2025.
IMVARIA announced FDA marketing authorization for Fibresolve, a non-invasive AI tool for lung fibrosis diagnosis, and the adoption of CPT billing codes.
IMVARIA announced FDA 510(k) clearance for ScreenDx, an AI-powered tool to assist in assessing ILD from CT scans.
IMVARIA collaborates with Mayo Clinic to develop AI for cancer analysis, starting with lung cancer, leveraging large datasets.
Fibresolve received FDA Breakthrough Device Designation and authorization, marking a milestone in AI healthcare technology.
IMVARIA reported results from multi-site clinical experiences with Fibresolve, the first FDA-authorized AI adjunctive diagnostic service for lung fibrosis, presented at ATS 2025.
IMVARIA announced FDA marketing authorization for Fibresolve, a non-invasive AI tool for lung fibrosis diagnosis, and the adoption of CPT billing codes.
IMVARIA announced FDA 510(k) clearance for ScreenDx, an AI-powered tool to assist in assessing ILD from CT scans.
IMVARIA collaborates with Mayo Clinic to develop AI for cancer analysis, starting with lung cancer, leveraging large datasets.
Fibresolve received FDA Breakthrough Device Designation and authorization, marking a milestone in AI healthcare technology.